HFrEF treatment — Research & Evidence

Q: What does the research say about HFrEF treatment?

The scientific consensus on HFrEF treatment is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for HFrEF treatment?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about HFrEF treatment?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Journal clubs discussing HFrEF treatment

Recent sessions

Inflammatory Hypothesis of CAD

STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended

Tri.Fr: The Heart of the Matter

OPCI Journal Club — Fri, Aug 7, 12:00 PM EDT

Cardiac intense unit demo

Cornell - Precision Medicine — Thu, Jul 23, 2:15 PM EDT

New data on Heart Failure Intervention

Synapse Team — Thu, Jul 16, 4:00 PM EDT

Frontiers in Precision Medicine Journal Club | Opening Session

Cornell - Precision Medicine — Fri, Jul 3, 12:00 PM EDT — 1 attended

GLP 1 new data

U Miami Journal Club — Thu, Jun 18, 2:00 PM EDT — 1 attended

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on HFrEF treatment

Effect of angiotensin converting enzyme inhibition on the incidence of restenosis after percutaneous transluminal coronary angioplasty

Catheterization and Cardiovascular Diagnosis — Brozovich F — Aug 1991

Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities

European Journal of Heart Failure — Quarta G — Jul 2020

Practical outpatient management of worsening chronic heart failure

European Journal of Heart Failure — Girerd N — Apr 2022

Mitral regurgitation during a myocardial infarction – New predictors and prognostic significance at two years of follow-up

Acute Cardiac Care — Barra S — Feb 2012

Impact of Functional Tricuspid Regurgitation on Heart Failure and Death in Patients with Functional Mitral Regurgitation and Left Ventricular Dysfunction

Stay current on HFrEF treatment

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Journal Club takes on HFrEF treatment

Evidence brief: HFrEF treatment

HFrEF treatment (also known as HFrEF, systolic heart failure, reduced EF heart failure). Heart failure with reduced ejection fraction therapies

As of 2026-08-14, the scientific consensus on HFrEF treatment is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on HFrEF treatment. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfref-treatment.

Deterministic synthesis from Synapse's enriched corpus — 206 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for HFrEF treatment?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest HFrEF treatment research

Explore every HFrEF treatment paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search HFrEF treatment papers